Therapy

Why?

• Patients given magnesium sulphate have no clear reduction in mortality, reinfarction or arrhythmias, but are at increased risk of developing heart failure, cardiogenic shock and severe hypotension. ^a

Magnesium sulphate increases the risk of heart failure and severe hypotension

Patient a	Treatment	Comparison	Outcome	CER	RRR (95% CI)	NNT (95% CI)
myocardial infarction	magnesium sulphate	placebo	heart failure at 5 weeks	16%	-7% (-11% to -3%)	-84 (-170 to -56)
			cardiogenic shock at 5 weeks	4.0%	-11% (-20% to -3%)	-220 (-750 to -130)
			treatment withdrawal due to severe hypotension at 24 hours	4.7%	-110% (-120% to -96%)	-20 (-21 to -18)